Cancer is one of the most common and serious diseases worldwide. In terms of mortality, it is the second leading cause of death, just behind cardiovascular disease. Education and prevention are fundamental to the fight against cancer.
Read More
Cancer is one of the most common and serious diseases worldwide. In terms of mortality, it is the second leading cause of death, just behind cardiovascular disease. Education and prevention are fundamental to the fight against cancer.
Read More
The FANTOM project (Future of ALCL: Novel Therapies, Origins, Biomarkers and Mechanisms of Resistance) is a prestigious international network funded under the Marie Skłodowska-Curie Actions – Doctoral Networks (MSCA DN).
Read More
New applications of sustainable, scalable, standardized, and cost-effective human biomaterials for cell-based assays, tissue engineering, and regenerative medicine.
Read More
From June to September 2025, I completed a secondment at the Division of Cellular and Molecular Pathology, University of Cambridge, United Kingdom
Read More
FANTOM students recently took part in the first in-person conference of the Young NHL Network (yNHL), held at Queens’ College, University of Cambridge in October 2025.
Read More
FANTOM Students Present at International Non-Hodgkin Lymphoma Symposium in New York
Read More
Big congratulations to Stefania Massari from the Medical University of Vienna for winning the Best Poster Award, and to Aiindrila Dhara from Masaryk University
Read More
Katarina Mišura has been awarded the prestigious Fellinger Krebsforschung grant, a significant recognition of her promising work in cancer research.
Read More
During my time in the Egger Lab at the “Medizinische Universität Wien”, I had the pleasure of working with Kristina Draganić to isolate primary macrophages from the whole blood of healthy donors.
Read More
Julia Montague, Enrique Abarca Ríos, and Rebekka Salzmann had the opportunity to represent the FANTOM network at the 30th Congress of the European Hematology Association (EHA) in Milan.
Read More